Want to see AXSM full AI Analyst Report?

Axsome Therapeutics (AXSM) Price & Analysis

2,389 Followers

AXSM Stock Chart & Stats

$241.00

-$0.53(-0.22%)

At close: Jul 24 4:00 PM EDT

$241.00

-$0.53(-0.22%)

Day’s Range― - ―

52-Week Range$96.09 - $260.19

Previous CloseN/A

Volume461.99K

Average Volume (3M)1.02M

Market Cap

$11.22B

Enterprise Value$8.57K

Total Cash (Recent Filing)$305.11M

Total Debt (Recent Filing)$219.90M

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Aug 10, 2026

EPS Estimate

-0.89

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.73

Shares Outstanding51,459,766

10 Day Avg. Volume706,319

30 Day Avg. Volume1,019,090

Financial Highlights & Ratios

PEG Ratio1.29

Price to Book (P/B)102.90

Price to Sales (P/S)14.23

P/FCF Ratio-96.78

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$285.50

Price Target Upside18.46% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-2.28

Revenue Forecast (FY)$971.90M

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth & High Gross MarginsAxsome has scaled product sales quickly while maintaining very high gross margins, showing attractive product economics. Durable top-line expansion and strong gross margins support reinvestment in commercialization and R&D, improving the odds of reaching operating leverage and long-term profitability.

AUVELITY New FDA Indication (Alzheimer’s Agitation)The new first-in-class AUVELITY indication meaningfully expands the addressable market into Alzheimer’s agitation. This regulatory win is structural, creating a durable commercial opportunity that can diversify revenue, increase prescriber adoption, and materially raise long-term peak sales potential.

SUNOSI Long-term U.S. Exclusivity SecuredThe patent settlement removes legal overhang and locks in extended U.S. exclusivity for SUNOSI through defined 2040 dates, materially reducing litigation risk. That extended protection provides predictable revenue visibility for a marketed product and supports longer-term cash flow planning.

Bears Say

Elevated Leverage And Thin Equity BaseAxsome’s capital structure shows high leverage relative to a small equity cushion, reducing financial flexibility. For a company still burning cash, elevated debt magnifies refinancing and covenant risk, constraining options for funding growth or absorbing setbacks without dilutive or costly financing.

Persistent Negative Cash GenerationOperating cash flow remains negative, and free cash flow is materially below zero, indicating ongoing burn even as revenues rise. This structural cash deficit forces reliance on external funding or rapid margin improvement to achieve sustainable operations and makes the runway sensitive to commercial or regulatory execution risks.

High SG&A And Gross‑to‑net PressureAggressive salesforce expansion and DTC investment have driven SG&A sharply higher while elevated gross‑to‑net deductions reduce realized revenue. Together these structural cost and reimbursement pressures compress margins and extend the time needed to convert top‑line growth into sustainable profitability.

Axsome Therapeutics News

Axsome Therapeutics price target lowered to $306 from $310 at Mizuho

Mizuho lowered the firm’s price target on Axsome Therapeutics (AXSM) to $306 from $310 and keeps an Outperform...

5d ago

AXSM

Shopify downgraded, Five Below upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

14d ago

Axsome Therapeutics initiated with an Outperform at BMO Capital

BMO Capital analyst Malcolm Hoffman initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price...

15d ago

AXSM

Axsome Therapeutics initiated with an Outperform at BMO Capital

BMO Capital initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price target Published first...

15d ago

AXSM

Axsome Therapeutics announces FDA acceptance of AXS-12 NDA

Axsome Therapeutics (AXSM) announced that the FDA has accepted for filing the company’s new drug application for AXS-12...

21d ago

AXSM

Axsome Therapeutics price target raised to $304 from $302 at RBC Capital

RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics (AXSM) to $304 from $302...

29d ago

AXSM

Axsome, Five Below, APPS, Intuit, Adobe Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($AXSM) ), ( ($FIVE) ), ( ($APPS) ), ( ($INTU)...

11d ago

ADBE

APPS

Axsome Advances AXS-14 Fibromyalgia Trial With New Long-Term Safety Update

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. The Phase 3 study “An Open-Label...

11d ago

AXSM

Axsome’s CLARITY Trial Targets Sleepy Depression: What Investors Should Watch

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Axsome Therapeutics, Inc. is running a...

11d ago

AXSM

Axsome’s Phase 3 Fibromyalgia Trial of AXS-14 Takes Shape: What Investors Should Watch

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Axsome Therapeutics, Inc. is running a...

11d ago

AXSM

Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating

Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

28d ago

AXSM

Blair adds American Express, Oracle to Conviction List in monthly update

William Blair analysts, in their monthly update, added the following stocks to its Analyst Conviction List: American Express...

1M ago

Axsome Therapeutics doses first patient in FOCUS-3 trial

Axsome Therapeutics (AXSM) announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating...

1M ago

AXSM

Axsome Therapeutics price target raised to $300 from $275 at TD Cowen

TD Cowen analyst Joseph Thome raised the firm’s price target on Axsome Therapeutics (AXSM) to $300 from $275...

2M ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was $96.09 and its highest was $260.19 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $11.22B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Aug 10, 2026 which is in 5 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on May 04, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$0.844 by -$0.416.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.89.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 51,459,766 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -$1.26 in its last earnings report, missing expectations of -$0.844. Following the earnings report the stock price went up 8.314%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in AXSM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Axsome Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

19.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Axsome Therapeutics (AXSM) Earnings & Revenues

Historic Earnings Reports

AXSM Company Deck

AXSM Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys strong commercial momentum and multiple material positive milestones: 57% YoY revenue growth, AUVELITY's new FDA approval and upgraded $8B peak-sales outlook, sales-force expansions, meaningful payer wins, and an advancing late-stage pipeline with recent BD adding AXS-20. Offsetting risks include materially higher SG&A, elevated gross-to-net discounts (notably for SYMBRAVO), a modest widening of net loss, a slight decline in cash, and remaining clinical/regulatory uncertainties for several pipeline assets. On balance, the positives (robust revenue growth, regulatory wins, and clear commercial execution) significantly outweigh the near-term financial and access headwinds.View all AXSM earnings summaries

AXSM Stock 12 Month Forecast

Average Price Target

$285.50

▲(18.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"102":"$102","381":"$381","171.75":"$171.8","241.5":"$241.5","311.25":"$311.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":285.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$285.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":242,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$242.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[102,171.75,241.5,311.25,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.99,230.4523076923077,242.9146153846154,255.37692307692308,267.83923076923077,280.3015384615385,292.76384615384615,305.22615384615386,317.6884615384615,330.15076923076924,342.6130769230769,355.0753846153846,367.5376923076923,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.99,223.18307692307692,228.37615384615384,233.56923076923078,238.7623076923077,243.95538461538462,249.14846153846153,254.34153846153845,259.5346153846154,264.72769230769234,269.9207692307692,275.11384615384617,280.30692307692306,{"y":285.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.99,219.83692307692309,221.68384615384616,223.53076923076924,225.3776923076923,227.2246153846154,229.07153846153847,230.91846153846154,232.76538461538462,234.6123076923077,236.45923076923077,238.30615384615385,240.15307692307692,{"y":242,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >